Notice of Temporary Suspension of Imports for the Medications Haldol (haloperidol) and Haldol Decanoate(haloperidol decanoate)
In accordance with Resolution RDC No. 18/2014, issued by Anvisa (the Brazilian Health Regulatory Agency), the company Moksha8 Brasil Indústria e Comércio de Medicamentos Ltda, headquartered at Avenida Ibirapuera, 2332, Tower I, 13th floor, Indianópolis, São Paulo/SP, registered with the CNPJ under No. 07.591.326/0001-80, hereby informs that, on February 5, 2026, it notified the Health Authority via files 0122086/26-1 and 0122035/26-7 that imports into Brazil of the drugs Haldol (haloperidol) and Haldol Decanoate, respectively, in the presentations described below, will be temporarily suspended.
These discontinuations are due to delays in shipping the products to Brazil and the need to complete mandatory technical procedures, which ensure the drug’s approval for sale in the country. With a focus on the well-being of Brazilian patients, it is important to note that, despite the temporary discontinuation of imports of Haldol and Haldol Decanoate, there are therapeutic alternatives available on the domestic market with the same indication and therapeutic class. Thus, patients will not be left without care. If you have any questions or need additional information, the company’s team is available to assist you by phone at 0800 601 9392 or by email at br.sac@arceralifesciences.com.